Idiotype network induced by anti-GD2 immunotherapy is associated with long-term survival in patients with neuroblastoma.

被引：0
|
作者：
Suzuki, Maya [1 ]
Cheung, Irene Y. [1 ]
Cheung, Nai-Kong V. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.10570
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10570
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
    Cabral, Jennifer
    Fernandez, Erica, I
    Toy, Bonnie
    Secola, Rita
    PEDIATRIC DRUGS, 2023, 25 (01) : 13 - 25
  • [22] Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
    Jennifer Cabral
    Erica I. Fernandez
    Bonnie Toy
    Rita Secola
    Pediatric Drugs, 2023, 25 : 13 - 25
  • [23] Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
    Blom, Thomas
    Lurvink, Roosmarijn
    Aleven, Leonie
    Mensink, Maarten
    Wolfs, Tom
    Dierselhuis, Miranda
    van Eijkelenburg, Natasha
    Kraal, Kathelijne
    van Noesel, Max
    van Grotel, Martine
    Tytgat, Godelieve
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [24] Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy
    Liu, Xiaoming
    Wills, Carson A.
    Chen, Longgui
    Zhang, Jiawen
    Zhao, Yuanjun
    Zhou, Mi
    Sundstrom, Jeffrey M.
    Schell, Todd
    Spiegelman, Vladimir S.
    Young, Megan M.
    Wang, Hong-Gang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [25] Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy
    Kushner, Brian H.
    LaQuaglia, Michael P.
    Cardenas, Fiorella Iglesias
    Basu, Ellen M.
    Gerstle, Justin T.
    Kramer, Kim
    Roberts, Stephen S.
    Wolden, Suzanne L.
    Cheung, Nai-Kong V.
    Modak, Shakeel
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (12) : 2019 - 2031
  • [26] Stage 4N neuroblastoma before and during the era of anti-GD2 immunotherapy
    Kushner, Brian H.
    Modak, Shakeel
    LaQuaglia, Michael P.
    Basu, Ellen M.
    Gerstle, Justin T.
    Cardenas, Fiorella Iglesias
    Kramer, Kim
    Roberts, Stephen S.
    Wolden, Suzanne L.
    Cheung, Nai-Kong V.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Modulating anti-GD2 immunotherapy via dual DFMO and TGF-β inhibition in neuroblastoma
    Gandhi, Om H.
    Turn, Christina S.
    Liu, Kangning
    Vu, Annette T.
    Bassiri, Hamid
    Hogarty, Michael D.
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
    Mora, Jaume
    Castaneda, Alicia
    Colombo, Maria Cecilia
    Gorostegui, Maite
    Gomez, Fernando
    Mane, Salvador
    Santa-Maria, Vicente
    Garraus, Moira
    Macias, Napoleon
    Perez-Jaume, Sara
    Munoz, Oscar
    Munoz, Juan Pablo
    Barber, Ignasi
    Sunol, Mariona
    CANCERS, 2021, 13 (06) : 1 - 18
  • [29] In Vivo Validation of Trogocytosis in Neuroblastoma: A Potential Novel Mechanism of Resistance to Anti-GD2 Immunotherapy
    Zamora, Abigail K.
    Zobel, Michael John
    Sheard, Michael Allen
    Seeger, Robert Charles
    Kim, Eugene Sung-Kyun
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (04) : S203 - S203
  • [30] Treatment-Related Toxicities During ANTI-GD2 Immunotherapy in High-Risk Neuroblastoma Patients in the Netherlands
    Blom, T.
    Lurvink, R.
    Aleven, L.
    Wolfs, T.
    Mensink, M.
    Dierselhuis, M.
    Van Eijkelenburg, N.
    Kraal, K.
    Van Noesel, M.
    Van Grotel, M.
    Tytgat, G.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S279 - S279
12345